Randomized Master Protocol for Immune Modulators for Treating COVID-19
Latest Information Update: 01 Feb 2024
At a glance
- Drugs Abatacept (Primary) ; Cenicriviroc (Primary) ; Infliximab (Primary) ; Dexamethasone; Remdesivir
- Indications COVID 2019 infections; COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms ACTIV-1 IM
- 10 Jul 2023 Results investigating whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia , published in the JAMA: the Journal of the American Medical Association
- 02 Jun 2022 Results presented in a Bristol-Myers Squibb Media Release.
- 02 Jun 2022 According to a Bristol-Myers Squibb media release, the full report on these data will be published in a peer-reviewed scientific journal. Given the positive findings from the topline data, Bristol Myers Squibb plans to discuss these data and potential next steps with the U.S. Food and Drug Administration.